175 related articles for article (PubMed ID: 36263515)
61. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
62. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
[TBL] [Abstract][Full Text] [Related]
63. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
64. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Moscetti L; Vici P; Gamucci T; Natoli C; Cortesi E; Marchetti P; Santini D; Giuliani R; Sperduti I; Mauri M; Pizzuti L; Mancini ML; Fabbri MA; Magri V; Iezzi L; Sini V; D'Onofrio L; Mentuccia L; Vaccaro A; Ramponi S; Roma CL; Ruggeri EM
Breast; 2016 Oct; 29():96-101. PubMed ID: 27476084
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
66. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
67. [Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Yamamoto D; Tsubota Y; Sueoka N; Yamamoto C; Kon M
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1319-21. PubMed ID: 26489585
[TBL] [Abstract][Full Text] [Related]
68. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
69. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
Jerusalem G; Rorive A; Collignon J
Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
[TBL] [Abstract][Full Text] [Related]
70. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T; Marschner N; Muendlein A; Welt A; Hagen V; Rauh J; Schröder H; Jaehnig P; Potthoff K; Lerchenmüller C
Breast Cancer Res Treat; 2019 Aug; 176(3):637-647. PubMed ID: 31115844
[TBL] [Abstract][Full Text] [Related]
71. Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Xie Y; Zhao Y; Gong C; Chen Z; Zhang Y; Zhao Y; Yuan P; Hu S; Li Y; Hu X; Zhang J; Wang L; Wang B
Sci Rep; 2019 Feb; 9(1):1710. PubMed ID: 30737426
[TBL] [Abstract][Full Text] [Related]
72. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
[TBL] [Abstract][Full Text] [Related]
73. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH; Karabulut B; Lee KS; Park BW; Adhav A; Cinkir HY; Abdel-Razeq H; Chang YC; Aksoy S; Im SA; Jeong J; Chae Y; Bowles J; Slimane K; Xue H; Kim SB
Breast Cancer Res Treat; 2021 Jul; 188(1):77-89. PubMed ID: 33728524
[TBL] [Abstract][Full Text] [Related]
74. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
[TBL] [Abstract][Full Text] [Related]
75. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Diaby V; Adunlin G; Zeichner SB; Avancha K; Lopes G; Gluck S; Montero AJ
Breast Cancer Res Treat; 2014 Sep; 147(2):433-41. PubMed ID: 25012857
[TBL] [Abstract][Full Text] [Related]
76. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Yi Z; Liu B; Sun X; Rong G; Wang W; Li H; Guan X; Li L; Zhai J; Li C; Qian H; Ma F; Xu B
Breast; 2020 Aug; 52():17-22. PubMed ID: 32335491
[TBL] [Abstract][Full Text] [Related]
77. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
[TBL] [Abstract][Full Text] [Related]
78. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
79. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
80. Early Changes of the Standardized Uptake Values (SUV
Sirico M; Bernocchi O; Sobhani N; Giudici F; Corona SP; Vernieri C; Nichetti F; Cappelletti MR; Milani M; Strina C; Cervoni V; Barbieri G; Ziglioli N; Dester M; Bianchi GV; De Braud F; Generali D
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182575
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
